Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TISA-818 in healthy adult subjects
NCT07337044Phase 1Completed
- Sponsor
- EnliTISA
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing TISA-818 group with Placebo group (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 20 days. Started Jan 2024; status: completed.
02
Drugs
TISA-818
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07337044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337044.